Unknown

Dataset Information

0

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.


ABSTRACT: RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve efficient delivery of siRNAs into cells in vivo, including into tumor and/or host cells in the tumor micro-environment (TME). Consequently, lipid and polymer-based nanoparticle siRNA delivery systems have been developed to surmount these physiological barriers. In this article, we review the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation. We also discuss the use of various types of lipid and polymer-based carriers for cancer therapy, including a section on anti-tumor nanovaccines enhanced by siRNAs. Finally, we review current and recent clinical trials using NPs loaded with siRNAs for cancer therapy. The siRNA cancer therapeutics field is rapidly evolving, and it is conceivable that precision cancer therapy could, in the relatively near future, benefit from the combined use of cancer therapies, for example immune checkpoint blockade together with gene-targeting siRNAs, personalized for enhancing and fine-tuning a patient's therapeutic response.

SUBMITTER: Mainini F 

PROVIDER: S-EPMC7321291 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.

Mainini Francesco F   Eccles Michael R MR  

Molecules (Basel, Switzerland) 20200610 11


RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve efficient delivery of siRNAs into cells in vivo, including into tumor and/or host cells in the tumor micro-environment (TME). Consequently, lipid and polymer-based nanoparticle siRNA delivery systems have been developed to surmount these physiol  ...[more]

Similar Datasets

| S-EPMC3703404 | biostudies-literature
| S-EPMC5626580 | biostudies-literature
| S-EPMC4307782 | biostudies-literature
| S-EPMC5522105 | biostudies-literature
| S-EPMC5308083 | biostudies-literature
| S-EPMC2833237 | biostudies-literature
| S-EPMC4077924 | biostudies-literature
| S-EPMC4729768 | biostudies-literature
| S-EPMC7594708 | biostudies-literature
| S-EPMC3889191 | biostudies-literature